Hangzhou, China – From November 2 to November 4, Dongguan Kewei Medical Instrument Co., Ltd. ("Dongguan Kewei"), a wholly owned subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), attended the 17th National Thoracic and Cardiovascular Surgery Congress held in Hangzhou to host a satellite meeting and display its occluders and extracorporeal circulation products.
On November 4, Dongguan Kewei hosted a satellite meeting on "the Application of EverMend™ Occluder in the Treatment of Congenital Heart Disease ("CHD")". Director Weida Zhang of General Hospital of Guangzhou Military Command of PLA and Director Jianming Wang of Children's Hospital of Hebei Province were invited as co-chairmen of the meeting. Director Qi Xie of Fujian Provincial Hospital, Director Jian Zuo of the First Affiliated Hospital of the Fourth Military Medical University, Director Tao Ma of General Hospital of Guangzhou Military Command of PLA, and Director Junping Yao of Children's Hospital of Hebei Province were invited to deliver speeches respectively regarding "the Surgical and Interventional Treatment of CHD with MicroPort®Occluder," "Evaluation of EverMend™ Occluder Treatment Efficacy and Safety", "Transthoracic Occlusion Technique and Complication Prevention", and "Clinical Experience in EverMend™ Occluder". Many of them spoke highly of Dongguan Kewei's EverMend™ Occluder for its high safety, low occurrence rate of complications, as well as excellent safety and short- and long-term efficacy.
The EverMend™ Occluder series include PDA, ASD, VSD and delivery systems. Compared to competitors in the market, EverMend™ has advantages in mesh frame, membrane of occluder and delivery systems. Its mesh frame adopts high-performance nitinol material, which features excellent hyperelasticity, resilience, and biocompatibility. Its waist uses patent fabric PET membrane and double-layered non-woven fabric, which has a better effect of blocking blood flow and tissue repair. Its delivery system is made of imported reinforced PTFE material to ensure the intensity and resilience of the sheath while achieving bigger inner diameter, making it easier for clinical operation.
During this meeting, experts exchanged ideas regarding the application of EverMend™ Occluder, and their excellent clinical performance and product quality further enhanced the experts' recognition in Dongguan Kewei's occluders, which is expected to help further promote the products so as to benefit more CHD patients.